SCM
Silverarc Capital Management Portfolio holdings
AUM
$691M
1-Year Est. Return
223.03%
1 Year Est. Return
+223.03%
AUM
$489M
AUM Growth
+$9.97M
(+2.1%)
Holding
83
Top Buys
| 1 | +$14.1M | |
| 2 | +$12.1M | |
| 3 | +$11.4M | |
| 4 |
Vaxcyte
PCVX
|
+$9.36M |
| 5 |
UroGen Pharma
URGN
|
+$8.79M |
Top Sells
| 1 | +$17.7M | |
| 2 | +$15.5M | |
| 3 | +$11.7M | |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$8.49M |
| 5 |
Wave Life Sciences
WVE
|
+$8.49M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PTC Therapeutics
PTCT
$6.05B
| – | – |
-60,389
|
|
||
77
Solid Biosciences
SLDB
$330M
| – | – |
-452,239
|
|
||
78
Tarsus Pharmaceuticals
TARS
$3.1B
| – | – |
-81,331
|
|
||
79
Travere Therapeutics
TVTX
$3.09B
| – | – |
-408,849
|
|
||
80
Unicycive Therapeutics
UNCY
$122M
| – | – |
-241,349
|
|
||
|
VXRT
81
DELISTED
Vaxart
VXRT
| – | – |
-683,825
|
|
||
|
82
Wave Life Sciences
WVE
$1.18B
| – | – |
-1,050,374
|
|
||
83
State Street SPDR NYSE Technology ETF
XNTK
$1.43B
| – | – |
0
|
|